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Two PTP receptors mediate CSPG 
inhibition by convergent and 
divergent signaling pathways in 
neurons
Yosuke Ohtake1,2, Daniella Wong1, P. M. Abdul-Muneer1,2, Michael E. Selzer1,3 & Shuxin Li1,2
Receptor protein tyrosine phosphatase σ (PTPσ) and its subfamily member LAR act as transmembrane 
receptors that mediate growth inhibition of chondroitin sulfate proteoglycans (CSPGs). Inhibition of 
either receptor increases axon growth into and beyond scar tissues after CNS injury. However, it is 
unclear why neurons express two similar CSPG receptors, nor whether they use the same or different 
intracellular pathways. We have now studied the signaling pathways of these two receptors using N2A 
cells and primary neurons derived from knockout mice. We demonstrate that both receptors share certain 
signaling pathways (RhoA, Akt and Erk), but also use distinct signals to mediate CSPG actions. Activation 
of PTPσ by CSPGs selectively inactivated CRMP2, APC, S6 kinase and CREB. By contrast LAR activation 
inactivated PKCζ, cofilin and LKB1. For the first time, we propose a model of the signaling pathways 
downstream of these two CSPG receptors. We also demonstrate that deleting both receptors exhibits 
additive enhancement of axon growth in adult neuronal cultures in vitro. Our findings elucidate the novel 
downstream pathways of CSPGs and suggest potential synergy of blocking their two PTP receptors.
After CNS injuries, a family of extracellular matrix (ECM) molecules, the chondroitin sulfate proteoglycans 
(CSPGs), are highly upregulated by reactive scars and potently inhibit axon growth into and beyond the lesion 
area1–3. CSPGs may be attached to cell membranes and usually form perineuronal nets by linking with several 
elements of the ECM, including hyaluronan, tenascin R and other molecules. The inhibitory effect of CSPGs 
on axon extension has been known for over 25 years4,5, but the underlying molecular mechanisms are not well 
understood6,7. CSPGs consist of glycosaminoglycan (GAG) chains attached to core proteins, and both compo-
nents exert inhibition on neurite outgrowth8.
The presence of sulfated GAG chains is particularly important because removing GAGs or preventing GAG sul-
fation neutralizes most of the suppression of axon growth by CSPGs in vitro9–11. Although CSPGs may block growth 
by sterically hindering growth-promoting adhesion molecules (such as laminins/integrins) and facilitating inhibi-
tion by chemo-repulsive molecules, such as Sema 3a and 5a12–14, several receptors appear important in conveying 
CSPG inhibition, including PTPσ , LAR, and Nogo receptors (NgR) 1 and 315–19. In particular, two members of the 
LAR subfamily, PTPσ and LAR, bind CSPGs with high affinity and mediate their suppression of axon elongation.
Deficiency of PTPσ or LAR in adult mice increased regrowth of various projection tracts after spinal 
cord injury (SCI), including sensory, corticospinal and serotonergic axons, into the caudal spinal cord15,17,18. 
Pharmacological blockade of LAR or PTPσ with small peptides stimulated regrowth of serotonergic axons and 
functional recovery after transection or contusion SCI16,19. However, the downstream signals mediating the effects 
of these two similar receptor-type PTPs (RPTPs) and the molecular basis for their requirement by neurons are 
not known. Nor is it known whether blocking both receptors would exert identical or synergistic therapeutic 
actions. We have now studied the intracellular signaling pathways that mediate CSPG-LAR/PTPσ interactions 
and compared their effects on the activities of multiple signaling proteins in cultures of a neuronal cell line, N2A. 
We further confirmed our findings in N2A cells with primary cultures of postnatal cerebellar neurons derived 
from PTPσ or LAR knockout mice. We demonstrate that LAR and PTPσ employ some signaling pathways in 
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common, including RhoA, Akt, extracellular-signal-regulated kinase (Erk) and microtubule-associated-protein 
1B (MAP1B). Their actions in transmitting CSPG effects to inhibit axon growth also involve distinct signals, 
including the use by PTPσ of collapsin response mediator protein 2 (CRMP2), adenomatous polyposis coli 
(APC), S6 ribosomal protein (S6) and cAMP response element-binding protein (CREB), and the use by LAR of 
cofilin, protein kinase C ζ (PKCζ ) and liver kinase B1 (LKB1). Consistent with this, deletion of both receptors 
showed additive enhancement of axon growth in adult neurons in vitro.
This study supports a novel model of signaling pathways downstream of the two CSPG receptors and potential 
synergistic actions of blocking both simultaneously.
Results
RhoA signaling mediates actions of both receptors, LAR and PTPσ. RhoA is a prominent intra-
cellular signal that regulates cytoskeletal dynamics, transcription and cell growth, and is thought to mediate 
functions of multiple axon growth inhibitors, including myelin- associated inhibitors20, CSPGs21,22 and guidance 
cues Sema 3a and Ephrin23,24. Inhibition of RhoA by C3 and the non-steroidal anti-inflammatory drugs ibuprofen 
and indomethacin, or of its downstream Rho kinase (Rock) by Y27632, Fasudil and dimethylfasudil, overcame 
CSPG-triggered inhibition and promoted neurite outgrowth in various cell types, including dorsal root ganglion 
(DRG) neurons21, Ntera-2 cells25 and retina ganglion cells22. To test whether RhoA mediates the actions of PTPσ 
or LAR due to CSPG stimulation, we transfected N2A cells with PTPσ or LAR and stimulated the cells with a 
mixture of purified CSPGs (neurocan, phosphacan, versican and aggrecan, 1.5 μ g/ml) 48 hrs after transfection. 
Most N2A cells formed two or more neurites 2–3 days after culture (not shown), consistent with the neuronal 
character of this cell line26,27. We measured levels of active RhoA in cell lysates by precipitation with the rhotekin 
binding domain, which binds only the GTP-bound form of RhoA28,29.
Treatment with CSPGs for 20 min significantly increased active RhoA levels in N2A cells transfected with 
either PTPσ or LAR, compared with those in control cells (Fig. 1c). Because CSPG treatment did not activate 
RhoA in non-transfected N2A cells (Fig. 1d), the overexpressed PTPσ or LAR must have been responsible for 
any RhoA activation induced by CSPGs. Expression of LAR appeared to induce slightly greater RhoA activation 
than did PTPσ (1.34 vs. 1.87). Thus, RhoA activation resulted from interactions between CSPGs and each of the 
Figure 1. Effects of CSPG treatment on activities of RhoA in N2A cells transfected with LAR or PTPσ  
and in CGNs derived from postnatal PTPσ+/+ or PTPσ−/− mice. The levels of PTPσ or LAR protein  
were determined from lysates of N2A cells 48 hrs after transfection with control, PTPσ or LAR plasmid  
(a), or of CGN cultures (b) derived from PTPσ or LAR KO mice by Western blots. The levels of active RhoA 
were measured in lysates of N2A cells 48 hrs after PTPσ or LAR transfection or CGNs 24 hrs after cultures with 
pulldown assay (active RhoA) and Western blots. Application of a mixture of purified CSPGs (1.5 μ g/ml, for 
20 min) increased levels of active RhoA in both PTPσ and LAR (c) transfected cells and in PTPσ + /+ , but not 
PTPσ − /− , CGNs (e). In contrast, CSPG stimulation in N2A cells without PTPσ or LAR transfection did not 
alter the levels of active RhoA (calibrated with either total RhoA or actin, (d). The full-length blots are included 
in the Supplementary Information file.
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RPTPs separately. To confirm expression of CSPG receptor proteins, we used Western blots to measure the levels 
of PTPσ and LAR in N2A cells 2 days after transfection. Control cells expressed low levels of both proteins, but 
transfection with either PTPσ or LAR dramatically elevated the levels of the corresponding protein - 11 fold for 
PTPσ and 8 fold for LAR (Fig. 1a).
To validate the findings from N2A cells in primary neuronal cultures, we evaluated whether PTPσ or LAR 
deletion alters activities of intracellular signals, including active RhoA, in cultured cerebellar granule neurons 
(CGNs) following incubation in CSPGs. We could easily collect enough samples for multiple Western blot analy-
ses using CGN cultures derived from postnatal 7–10 day mice. Following 24 hours of growth, CGNs were treated 
with CSPGs (1.5 μ g/ml) for 20 minutes and the levels of active RhoA in the supernatants were detected by pre-
cipitation with rhotekin binding domain beads and then by Western blotting. Application of CSPGs at 1.5 μg/ml 
significantly enhanced levels of active RhoA in CGNs derived from PTPσ + /+ mice (Fig. 1e). However, appli-
cation of CSPGs (1.5 μ g/ml) failed to induce significant changes in active RhoA in cultured CGNs derived from 
PTPσ − /− mice. Similarly, we demonstrated that CSPG stimulation activated RhoA in LAR+ /+ CGNs, but not 
in LAR− /− neurons16. We confirmed the deficiency of PTPσ and LAR proteins in knockout CGNs (Fig. 1b).
As a downstream mediator of RhoA action, Rock can phosphorylate and activate LIM kinase (LIM-K), which 
in turn phosphorylates and inactivates cofilin30,31. As an actin binding protein, cofilin is critical to regulating 
actin dynamics, and phosphorylation of cofilin at Ser3 (inactive form) inhibits actin- depolymerizing activity at 
the minus end of filaments, thus preventing actin reassembly32,33. We examined levels of p-cofilin in N2A cells 
transfected with PTPσ or LAR and found dramatically elevated levels of p-cofilin in LAR-transfected but not 
PTPσ -transfected cells 30–120 min after incubation with CSPGs (Fig. 2a), suggesting that CSPG-LAR interac-
tions increase cofilin phosphorylation and inhibit axon elongation by reducing actin reassembly. Consistently, 
Rock inhibitors attenuated p-cofilin levels in PC12 cells due to CSPG stimulation34. CSPG stimulation for 
5–120 min also significantly enhanced the levels of p-cofilin in wild-type (WT) CGNs, but not in LAR− /− CGNs 
(Fig. 2b). Thus, inactivation of cofilin by phosphorylation appears important in mediating the inhibitory effects 
of CSPG-LAR, but not CSPG-PTPσ .
Akt/mTOR pathway conveys signals by the two CSPG receptors. The intracellular PI3K/Akt 
pathway is essential for regulating neuronal growth during development and contributes to suppression of axon 
growth by CSPGs16,21,22,35. We evaluated whether Akt and its downstream signals mediate some actions of the two 
CSPG receptors in cultures. Phosphorylation of Akt at residue Ser473 in its C-terminal hydrophobic motif is nec-
essary for its full activation, and cellular levels of p-Akt at Ser473 correlate with its activity36,37. CSPG stimulation 
reduced the levels of p-Akt in N2A cells transfected with either PTPσ or LAR (Fig. 2c). Consistently, application 
of CSPGs reduced levels of p-Akt in WT CGNs, but not in PTPσ − /− (Fig. 2d) or LAR− /− 16 neurons. These 
results indicate that Akt mediates actions of both receptors upon CSPG application, although PTPσ activation 
inactivates Akt at later time points (60–120 vs. 5–30 min).
Deletion of PTEN, a negative regulator of PI3K/Akt signaling, stimulated neuronal growth and survival fol-
lowing axotomy by activating mTOR38,39, a key signal regulating protein synthesis during cell growth. We exam-
ined whether mTOR pathways are modulated during CSPG-mediated inhibition by measuring p-S6 levels, which 
reflect mTOR activity40. Phosphorylation of the ribosomal protein S6, a downstream effector of mTOR, correlates 
well with increased translation of many mRNA transcripts and with cell growth. Overexpression of PTPσ , but not 
LAR, reduced levels of p-S6 in N2A cells after administration of CSPGs (Fig. 2e), suggesting that mTOR mediates 
the effects of the interactions between CSPGs and PTPσ , but not LAR. In support of this, CSPG stimulation atten-
uated levels of p-S6 in WT neurons, but not in PTPσ -deleted neurons (Fig. 2f). Of note, we compared alterations 
of several signaling proteins (RhoA, Cofilin, and Akt) calibrated with either total signaling proteins (Figs 1d and 
2a–d) or actin (Supplemental Fig. 1), and obtained identical results with either control (see Supplemental Table 1). 
We thus employed actin as the loading protein for the most other signaling proteins studied here. mTOR regulates 
cell growth also by phosphorylation of the translation repressor protein 4E-BP1, which releases the eukaryotic 
initiation factor 4E (eIF4E) and initiates protein translation during growth. 4E-BP1 is primed for subsequent 
phosphorylation at Ser65 and Thr70 after its phosphorylation at Thr37/46 by FRAP/mTOR41. Therefore, we also 
measured the levels of p-4E-BP1 (Thr37/46, inactive), but found that overexpression of either PTPσ or LAR 
induced only a trend toward slight reduction in p-4E-BP1 levels in response to CSPG stimulation (Fig. 3a; not 
significant). This result indicates that the role of 4E-BP1 in regulating CSPG-receptor interactions is minimal.
CRMP2 is critical for regulating axon formation and outgrowth during development by binding tubulin 
heterodimers and promoting microtubule assembly42–44. Because activation of Rock and glycogen synthase 3β 
(GSK-3β ), the downstream signal of Akt, contribute to axon growth cone collapse by phosphorylating and inacti-
vating CRMP245–48, we examined potential changes of p-CRMP2 at Thr514 (inactive), a target of GSK-3β . CSPG 
stimulation increased the levels of p-CRMP2 in PTPσ - but not LAR-transfected N2A cells (Fig. 3b), suggest-
ing that phosphorylation of CRMP2 contributes to axon growth inhibition caused by CSPG-PTPσ interactions. 
Indeed, application of CSPGs increased levels of p-CRMP2 in WT CGNs, but had no effect in PTPσ -deleted 
neurons (Fig. 3c).
APC and MAP1B mediate interactions between CSPGs and RPTPs. The tumor suppressor APC 
accumulates at the tip of the growth cone during axon elongation and its phosphorylation by GSK-3β suppresses 
axon growth by reducing its ability to bind microtubules49. Because Akt/GSK-3β signaling mediates CSPG func-
tion in PC12 cells and CNS neurons16,21,35, we evaluated the changes in p-APC levels after applying CSPG. This 
reduced p-APC levels in N2A cells transfected with PTPσ but not LAR (Fig. 3d). CSPGs similarly attenuated 
p-APC levels in WT CGNs, but not in PTPσ -deleted neurons (Fig. 3e). These data suggest that a reduction in 
APC levels is involved in mediating effects of CSPG-PTPσ interactions. As another well-known target of GSK-3β , 
MAP1B regulates microtubule dynamics in axon growth cones. In contrast to APC, phosphorylation by GSK-3β 
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Figure 2. Effects of CSPG application on activities of cofilin, Akt and S6 kinase in N2A cells or CGNs. PTPσ 
or LAR transfected N2A cells or CGNs derived from PTPσ or LAR KO mice were treated with purified CSPGs 
(1.5 μ g/ml) for different time points and the levels of phosphorylated Cofilin (p-Cofilin Ser3, inactive form), Akt 
(p-Akt s473, active form) and S6 kinase (p-S6 Ser235/236, active form) in cell lysates were measured by Western 
blots. CSPG stimulation enhanced levels of p-Cofilin in LAR transfected N2A cells (a) and in LAR+/+, not 
LAR− /− , CGNs (b). CSPG treatments decreased levels of p- Akt in both PTPσ and LAR transfected N2A 
cells (c) and in PTPσ + /+ , not PTPσ − /− , CGNs (d). Also, CSPGs reduced levels of p-S6 in PTPσ , not LAR, 
transfected N2A cells (e), and in PTPσ + /+ , not PTPσ − /− CGNs (f). The full-length blots are included in the 
Supplementary Information file.
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Figure 3. Effects of CSPGs on activities of 4E-BP1, CRMP2 and APC in N2A cells or CGNs. PTPσ or LAR 
transfected N2A cells or CGNs derived from PTPσ + /+ or PTPσ − /− CGNs were treated with purified CSPGs 
(1.5 μ g/ml) at different time points and the levels of phosphorylated 4E-BP1 (p-4E-BP1 Thr37/46, inactive 
form), CRMP2 (p-CRMP2 Thr514, inactive form) and APC (p-APC Ser2054, active form) in supernatants of 
cell lysates were measured by Western blots. CSPG stimulation did not alter levels of p- 4E-BP1 in either PTPσ 
or LAR transfected cells significantly (a). CSPGs increased levels of p-CRMP2 in PTPσ , not LAR, transfected 
N2A cells (b), and in PTPσ + /+ , not PTPσ − /− , CGNs (c). Also, CSPG applications attenuated levels of p-APC 
in PTPσ , not LAR, transfected N2A cells (d), and in PTPσ + /+ , not PTPσ − /− , CGNs (e). The full-length blots 
are included in the Supplementary Information file.
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at Thr1265 of MAP1B activates this protein and reduces microtubule dynamics in axons. Treatment with CSPGs 
enhanced the levels of p-MAP1B in N2A cells overexpressing either PTPσ or LAR (Fig. 4a), suggesting that 
MAP1B mediates actions of both LAR and PTPσ . In support of this, levels of MAP1B were increased in WT 
CGNs, whereas deletion of LAR, but not PTPσ , in CGNs largely eliminated the elevation of p-MAP1B lev-
els (Fig. 4b,c). Together, the GSK-3β substrates APC and MAP1B mediate functions of PTPσ , but APC is not 
involved in LAR action, and MAP1B appears to mediate the action of LAR to a greater degree than that of PTPσ .
Erk mediates actions of PTPσ and LAR by distinct downstream signaling pathways. 
Extracellular regulated kinases (Erks) are expressed in multiple cell types including neurons, and are essential 
for regulating protein synthesis/degradation and maintaining levels of proteins required for growth in response 
to many extracellular axon growth and guidance cues, including neurotrophins. Although it has not been 
determined whether Erk signaling mediates CSPG function, nerve growth factor (NGF) promoted growth of 
conditioning DRG neurons cultured on CSPGs50, suggesting a potential connection between the downstream 
activation of Erk by NGF and its neutralization of CSPG- mediated growth suppression. Therefore, we evaluated 
Erk activity by measuring phosphorylated p44/42 MAPK (Erk1/2) at Thr202/Tyr204. CSPG stimulation remark-
ably decreased levels of p-Erk in N2A cells transfected with either PTPσ or LAR (Fig. 4d). Importantly, CSPG 
application reduced levels of p- Erk in WT neurons, but deletion of either receptor alone failed to eliminate the 
inactivation effect on Erk signaling (Fig. 4e,f). These findings support that Erk signaling mediates actions of both 
RPTPs in neurons.
The 90 kDa ribosomal S6 kinases (p90RSKs), also known as MAPK-activated protein kinase 1, are Ser/Thr 
kinases characterized by two non-identical functional kinase domains and a carboxy-terminal docking site for 
Erks51,52. The MAPK/Erk pathway activates p90RSKs by phosphorylating them at several sites within and outside 
of the RSK kinase domain, including Thr573. We thus measured p90RSK activity, but did not detect significant 
alteration of p-p90RSK (Thr573) levels in N2A cells overexpressing either PTPσ or LAR (Fig. 5a), suggesting that 
p90RSK plays a negligible role in mediating the functions of these two CSPG receptors.
Activation of Erk can enhance CREB phosphorylation at serine 133, thus increasing its activity as an upstream 
signal53,54. Because Erk mediates actions of both PTPσ and LAR (Fig. 4d–f), we examined the level of p-CREB 
(Ser133) and detected its reduction in N2A cells transfected with PTPσ , but not LAR (Fig. 5b). CSPGs also 
reduced the levels of p-CREB (Ser133) in WT CGNs and LAR deficiency abolished this effect (Fig. 5c). Thus, 
CREB modulates the interactions between CSPGs and PTPσ as a signal downstream of Erk.
The serine/threonine kinase 11 (known as LKB1) and its downstream signaling target SAD/MARK regu-
late neuronal polarization and axon elongation during development55. Erk and RSK phosphorylate LKB1 at 
Ser325 and Ser428 (Ser431 in the mouse), which is critical for subsequent activation of AMP- activated protein 
kinase (AMPK)56. Because PTPσ and LAR activations suppress Erk activity, we examined the levels of p-LKB1 
at Ser431, which is required for neuronal polarization57. PTPσ overexpression in N2A cells did not affect levels 
of p-LKB1 Ser431, but LAR activation due to CSPG stimulation decreased its levels (Fig. 5d). Moreover, 
CSPGs decreased levels of p-LKB1 in WT CGNs and LAR deletion eradicated this effect (Fig. 5e). The levels of 
p-LKB1 calibrated with either total LKB1 (Fig. 5d,e) or actin (Supplemental Fig. 2) exhibited the same changes 
(see Supplemental Table 1). Thus, CSPG-LAR (but not -PTPσ ) interactions inactivate LKB1 signaling. On the 
other hand, cAMP- dependent PKA activates LKB1 by phosphorylating it at S431 and promotes axon differenti-
ation during development57–59. We therefore measured the levels of p-PKA at Thr197, but detected only a trend 
toward slight reduction in LAR-overexpressing N2A cells after CSPG application (Fig. 6a, not significant), sug-
gesting that PKA plays at most a minor role in mediating actions of the two RPTPs.
As a member of the atypical protein kinase C subfamily, PKCζ phosphorylates LKB1 at Ser-428/431 and 
mediates activation of AMPK in endothelial cells60,61. We measured p-PKCζ levels (Thr410/403) and detected 
its elevation in LAR- but not PTPσ -overexpressing cells following CSPG stimulation (Fig. 6b). CSPG treatment, 
however, reduced levels of p-PKCζ in WT but not LAR− /− CGNs (Fig. 6c). These experiments indicate that the 
PKCζ isoform contributes to LAR action upon CSPG application, probably by regulating LKB1 activity. Similarly, 
application of NG2, a non-lectican CSPG that is normally membrane-bound, regulated PKCζ activity in rat post-
natal neurons and contributed to axon growth inhibition by NG262. Because PKC appears to mediate actions of 
some axon growth inhibitors63, we also examined PKC activity by measuring levels of p-PKC-pan. In contrast, 
p-PKC was not altered in either LAR- or PTPσ -transfected cells following CSPG application (Fig. 6d). To confirm 
this result, we assessed its changes in CGN cultures and did not detect its alterations in either WT or LAR/PTPσ - 
deleted neurons (Fig. 6e,f). Therefore, PKC does not play a major role in CSPG-PTPσ /LAR interactions.
Our experimental results with either N2A cells or primary neurons support that LAR and PTPσ share certain 
signaling pathways, but also employ distinct signals to covey CSPG effects on neurons. It was thus important to 
determine whether targeting both PTP receptors would have additive actions in overcoming CSPG-mediated 
inhibition of axon growth. CSPG-spot assay is a reliable method for measuring axon growth in vitro by count-
ing the number of neurites that cross a gradient of CSPGs15,64, and we have demonstrated important roles for 
LAR and PTPσ in mediating the inhibition of axon growth by CSPGs with this and other models16,19. We now 
assessed whether deletion of both RPTPs would have synergistic actions in stimulating axon growth on a ring of 
high-concentration aggrecan. As shown in Fig. 7a, deleting either of these receptors enhanced neurite growth in 
adult DRG cultures on CSPGs, but DRGs derived from double KO mice exhibited a greater degree of axon growth 
compared to those from single KO animals. This finding suggests that the two RPTPs have synergistic effects in 
mediating CSPG suppression of axon growth in vitro.
Discussion
To compare downstream signals of the two RPTPs, we conducted parallel experiments, measuring alter-
ations of multiple signaling proteins in the lysates of PTPσ - or LAR-overexpressing N2A cells. These 
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Figure 4. Effects of CSPGs on activities of MAP1B and Erk in N2A cells or CGNs. PTPσ /LAR transfected 
N2A cells or CGNs derived from PTPσ or LAR KO mice were treated with purified CSPGs (1.5 μ g/ml) at several 
time points and the levels of phosphorylated MAP1B (p-MAP1B Thr1265, active form) and Erk (p-Erk1/2 p44/42 
Ser2054, active form) in the supernatants of cell lysates were examined by Western blots. CSPG application 
enhanced levels of p-MAP1B in both PTPσ and LAR transfected N2A cells (a) and in WT CGNs (b,c). LAR, not 
PTPσ , deletion largely eliminated the enhanced p-MAP1B. Moreover, CSPGs attenuated levels of p-Erk in both 
PTPσ and LAR transfected cells (d) and in PTPσ + /+ , PTPσ − /− , LAR+ /+ and LAR− /− CGNs (e,f), suggesting 
that deleting one of RPTPs does not eradicate CSPG effects on Erk signal and that Erk conveys actions of both 
receptors. The full-length blots are included in the Supplementary Information file.
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Figure 5. Effects of CSPGs on activities of p90RSK, CREB and LKB1 in N2A and CGN cultures. PTPσ /LAR 
transfected N2A cells or CGNs derived from PTPσ or LAR KO mice were treated with purified CSPGs (1.5 μg/ml) 
at several time points and the levels of phosphorylated p90RSK (p-p90RSK Thr573, active form), CREB (p-CREB 
Ser133, active form) and LKB1 (p-LKB1 Ser431, active form) in the supernatants of cell lysates were measured by 
Western blots. CSPGs did not alter levels of p-p90RSK in either PTPσ or LAR transfected N2A cells (a). CSPGs 
significantly decreased levels of p-CREB in PTPσ , not LAR, transfected N2A cells (b) and in PTPσ + /+ , not 
PTPσ − /− , CGNs (c). In contrast, CSPGs stimulation decreased levels of p-LKB1 in LAR, not PTPσ , transfected 
N2A cells (d) and in LAR+ /+ , not LAR− /− , CGNs (e). The full-length blots are included in the Supplementary 
Information file.
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Figure 6. Effects of CSPGs on activities of PKA, PKCζ and PKC-pan in N2A cell or CGN cultures. PTPσ 
/LAR transfected N2A cells or CGN cultures derived from PTPσ or LAR KO mice were treated with purified 
CSPGs (1.5 μ g/ml) at several time points and the levels of phosphorylated PKA (p-PKA Thr197, active form), 
PKCζ (p-PKCζ Thr410/403, active form) and PKC (p-PKC-pan Thr410, active form) in the supernatants of cell 
lysates were measured by Western blots. CSPGs did not alter levels of p-PKA in either PTPσ or LAR transfected 
N2A cells (a). CSPGs application increased levels of p-PKCζ in LAR, but not PTPσ , transfected N2A cells  
(b), but reduced levels of p-PKCζ in LAR+ /+ , not LAR− /− , CGNs (c). In contrast, CSPGs did not alter levels 
of p-PKC-pan in either PTPσ or LAR transfected N2A cells (d) and in PTPσ + /+ , PTPσ − /− , LAR+ /+ and 
LAR− /− CGNs (e, f). The full-length blots are included in the Supplementary Information file.
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neuroblastoma-derived cultures possess the functional properties of neurons26 by differentiating into neurons, 
extending neurites and responding to various neuronal growth regulators27,65–67, including chondroitin sul-
fate, the representative sulfated glycosaminoglycan attached to the core proteins of CSPGs68. N2A cells are thus 
frequently used to study neuronal differentiation, neurite outgrowth, synaptogenesis, and neuronal signaling 
pathways. Importantly, we validated our findings in primary neuronal cultures derived from single or double 
KO mice. Previously, we and other groups had demonstrated that CSPGs activate RhoA/GSK-3β signaling and 
Figure 7. Additive effects for promoting neurite growth by deletion of both PTPσ or LAR receptors and 
schematic of downstream signaling pathways for two PTP receptors of CSPGs. Representative examples of 
neurite outgrowth on aggrecan spots show that a number of neurites crossed the aggrecan rim in DRGs derived 
from adult mice with one or two receptor deficiency, in contrast to no neurite crossing in DRGs derived from 
WT mice. The numbers of neurites that crossed the aggrecan rims were quantified from different groups  
(a). n = 17–33 spots from two separate experiments. Based on our findings in this study, we proposed a novel 
model of signaling pathways downstream of the two CSPG receptors (b). CSPGs inhibit neuronal growth by 
binding and activating two PTP receptors, PTPσ and LAR. Intracellularly, activation of PTPσ and LAR by 
CSPGs activate RhoA-Rock signaling and inactivate Akt and Erk pathways. However, the two receptors employ 
distinct pathways downstream of RhoA/Rock, Akt/GSK-3β and Erk signals to effect CSPGs’ inhibition of axon 
growth. Red-filled: signals conveyed by PTPσ . Green-filled: signals conveyed by LAR. Yellow-filled: shared 
signals by both PTPσ and LAR. Ig-like: immunoglobulin-like domains; FN-III: fibronectin Type III domains; 
D1: D1 domain; D2: D2 domain. S6K: S6 kinase.
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inactivate Akt signaling21,22,34,35,69, thus defining the roles of RhoA and Akt in mediating CSPG-LAR interactions16 
in PC12 cells and mouse cerebellar neuron cultures. Therefore, the present results represent signaling pathways 
of general neuronal populations.
Based on the results of the present study and previous reports, we propose a simplified model of convergent 
and divergent pathways downstream of the two PTP CSPG receptors (Fig. 7b; see summary in Table 1). The inter-
actions between CSPGs and LAR/PTPσ lead to activation of intracellular RhoA and inactivation of Akt and Erk 
signals. These 3 pathways are known to regulate growth of multiple cell types and elongation of axons. CSPG stim-
ulation consistently activates RhoA and reduces phosphorylated Akt at Ser473 in LAR+ /+ , but not LAR− /− , cer-
ebellar neurons16. Deletion of PTPσ activates MAPK and Akt signals in adult mouse retinal cells70. Downstream 
of RhoA, activation of Rock by PTPσ , but not by LAR action, inactivates the microtubule-interacting protein 
CRMP2 (Fig. 3), thus suppressing neuronal growth. Similarly, activation of Rock due to CSPG-PTPσ interac-
tions appears to mediate outgrowth of oligodendrocyte processes and myelination71. In contrast, LAR-induced 
Rho activation is mediated by other signaling, including inactivation of the actin-binding protein cofilin (Fig. 2), 
which disassembles actin filaments and thus regulates dynamics of cytoskeleton during axon growth32,34,72,73.
PTPσ and LAR do not employ identical signaling to mediate CSPG actions, although both use the Akt/GSK-3β 
signaling pathway (Fig. 2). Activation of PTPσ by CSPGs alters activities of multiple microtubule-interacting pro-
teins, including inactivation of CRMP2 and APC, as well as activation of MAP1B (Figs 3 and 4). LAR activation 
by CSPGs also activates MAP1B, but does not alter the activities of CRMP2 and APC. Moreover, the action of 
PTPσ , but not LAR, is mediated by ribosomal S6 kinase, one of the well-known downstream signals of the Akt/
mTOR pathway. 4E-BP1, another well-known signal downstream of mTOR39, does not play a significant role in 
transmitting the actions of either PTPσ or LAR.
As a downstream signal for many neurotrophic factors74,75, Erk is linked to axon growth and regeneration76,77. 
CSPG and PTPσ /LAR interactions inactivate Erk signaling (Fig. 4), in addition to activating RhoA and inactivat-
ing Akt. Erk can phosphorylate and activate many substrates, some of which play important roles in controlling 
cell growth78. Among them, the ribosomal S6 kinases, including p70RSK (usually called S6 kinase) and p90RSK, 
are involved in neuronal signal transduction and growth59,79. We demonstrate that S6 kinase, but not p90RSK, 
contributes to the interactions between CSPGs and PTPσ (Figs 2 and 5) and that neither RSK conveys the action 
of LAR. Indeed, Erk phosphorylates S6 Kinase80 and its activation promotes axon regeneration after CNS injury81.
Moreover, activation of PTPσ , but not LAR, by CSPGs inactivated CREB by reducing its phosphorylation, 
suggesting that CSPG-PTPσ interactions inactivate Erk and subsequently reduce the activity of CREB, an impor-
tant transcription factor for controlling neuronal growth82. Actually, Erk can phosphorylate CREB at serine 133 
and thereby increase its activity53,54,83.
As a downstream signal of Erk, LKB1 appears to be critical for regulating axon elongation during development55. 
Our results measuring LKB1 Ser431 support a significant role for LKB1 in mediating the actions of LAR, but 
not PTPσ . Although LKB1 Ser325 is a direct phosphorylation target of Erk56, whether Erk phosphorylates LKB1 
Ser431 directly or indirectly is unclear. We thus examined other signaling proteins that potentially link LAR to 
LKB1 and found that CSPG application increased PKCζ activity in LAR-transfected N2A cells. However, while 
CSPG stimulation reduced levels of p-PKCζ in WT CGNs, it did not do so in LAR− /− CGNs. These findings 
suggest that CSPG-LAR interactions inactivate PKCζ signaling in neurons. Why CSPGs activated this kinase 
in LAR-overexpressing N2A cells remains to be studied. Taken together, our results support the notion that 
CSPG-stimulated LAR activity suppresses LKB1 signaling by inactivating PKCζ in neurons. In contrast, our 
results did not support major roles for PKC or PKA in mediating the actions of either PTPσ or LAR.
Why PTPσ and LAR employ both convergent and divergent downstream signaling pathways remains unclear. 
It may relate to diversity in the ligands and substrates of RPTPs, indirect links along the different intracellu-
lar pathways and multiple interactions among the signals. Although CSPGs and Although HSPGs appear to 
be the substrates of PTPσ and LAR15,16,84,85, the physical ligands of these receptors are incompletely identified. 
N-cadherin, β -catenin, and p250GAP are the reported substrates of RPTPs86, but PTPσ and LAR may have other 
unidentified substrates. Stimulation of many transmembrane receptors can activate RhoA and inactivate Akt/
Erk signals, but the interactions between different ligands and receptors may use diverse effectors to convey their 
functions. Various negative molecules for regulating cell growth, including CSPGs, myelin associated inhibitors 
and some repulsive guidance cues, can activate RhoA6,87, but they are unlikely to employ identical signaling path-
ways to suppress neuronal growth. Also, Rho signaling can regulate the activities of PTEN/Akt/mTOR proteins 
in some cell types, including macrophages, neutrophils88,89, and neurons90–92. The mechanisms by which RhoA is 
activated and Akt and Erk are inactivated by CSPG-RPTP interactions are still unknown.
To explain how PTPσ and LAR differ in their CSPG-signaling functions, we cannot exclude possible subtle 
roles of other signaling proteins that did not appear significantly altered by CSPG actions in the current experi-
ments. For example, given the trend of their slight alterations (Fig. 3), 4E-BP1 may moderately mediate actions 
of PTPσ , while both 4E-BP1 and APC may modestly regulate LAR function. Other signals that were not studied 
here may play roles for mediating functions of the CSPG receptors. Expression of constitutively active Rac and 
Cdc42 GTPases enhanced neurite outgrowth on CSPG substrate69 and Rac appears to modulate PTPσ activity 
through p250GAP and subsequent cytoskeleton dynamics93. Interrupting LAR function with a systemically deliv-
ered small peptide appears to activate Trk receptors and focal adhesion-associated protein kinase FAK94,95. Thus, 
it will be important to further study potential regulating functions of these and other signals.
We detected a crucial role of atypical PKCζ , but not the conventional PKC, in regulating CSPG-LAR inter-
actions (Fig. 6). In contrast, a previous study indicated that CSPG application enhanced activity of conventional 
PKC by increasing levels of p-PKC-pan63. It is likely that CSPGs activate PKC-pan by PTPσ -/LAR-independent 
pathways. Not only myelin-associated growth inhibitors, but also CSPGs signal axon growth inhibition by bind-
ing to Nogo receptors17,63. Therefore, it will be interesting to determine whether CSPGs activate PKC by interact-
ing with NgRs, especially NgR1 and 3. Because PKC is required for Rho activation by myelin-associated growth 
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inhibitors63, future studies also should be aimed at determining whether activation of PKCζ by CSPG-LAR inter-
actions has a similar effect on Rho activity.
In this study, we examined 15 signaling proteins that potentially act as the downstream pathways mediating 
the interactions between CSPGs and two PTP receptors (Table 1) and used actin as a loading control for some 
of them. We have confirmed the reliability of using actin as a loading control by performing comparison experi-
ments and demonstrating that the alterations of signaling proteins calibrated with either total signaling proteins 
or actin are basically identical in both types of cells (Supplemental Table 1). Consistently, actin has been proven 
to be a reliable loading control for multiple cultured cells and is widely used for studies with Western blot assay96. 
Because p-cofilin is a regulator of actin dynamics, we further confirmed its alterations in LAR-transfected N2A 
cells and WT CGNs by calibration with both total cofilin and actin.
In identifying the signaling pathways of the two CSPG receptors, we primarily employed one-way ANOVA 
to determine whether CSPG stimulation induces statistically significant differences at several time points. The 
overall alterations of the signaling proteins in N2A cells and CGN cultures matched well. Because the properties 
of N2A cells may not be identical to those of primary CGNs, the extents and latencies of the signaling changes 
might not be the same. For example, p-S6 showed a greater degree of reduction at more delayed time points in 
CGNs than in PTPσ -transfected N2A cells (Fig. 2e,f). However, we identified changes of the signaling proteins 
in N2A cells and confirmed them with primary cultures of postnatal CGNs. Therefore, our proposed model in 
Fig. 7b should apply to CNS neurons.
Conclusions
On the basis of the present results and previous studies, we summarize convergent and divergent pathways that 
mediate the axon growth-inhibitory effects of CSPG-RPTP interactions in Fig. 7b. This diagram highlights some 
areas where more studies are required to resolve apparent discrepancies. Both LAR and PTPσ activate RhoA/
Rock and inhibit Akt and Erk, but the mechanisms by which these effects are produced are not known. Although 
Rho/Rock inhibits both Cofilin and CRMP2, only LAR inhibits Cofilin and only PTPσ inhibits CRMP2. Similarly, 
mTOR/S6K and CREB are activated by Akt and Erk, but only PTPσ inhibited S6K and CREB signals. It thus is 
very important to further study intermediate signals downstream of PTPσ and LAR and their potential links 
with the identified pathways, including RhoA, Akt and Erk. Moreover, it will be interesting to determine whether 
specific interventions of the identified pathways (such as blocking or/and activating them) can alter the CSPG 
receptors-mediated responses and axon growth ability on CSPG substrates. Because we evaluated a large number 
of downstream signaling proteins in this study, it is beyond the scope of this paper to further investigate their 
significance in axon regeneration over CSPG inhibitors.
Transgenic or pharmacological inhibition of either PTPσ or LAR induces significant regrowth of several pro-
jection fiber tracts after SCI, including serotonergic, corticospinal and sensory fibers, and improves functional 
recovery16,18,19. Given widespread expression of these RPTPs in adult CNS15,16,97, their suppression should pro-
mote growth of other tracts, such as the rubrospinal, reticulospinal and propriospinal axons. Because PTPσ and 
LAR conveyed CSPG signaling by both convergent and divergent pathways, blocking both RPTPs simultaneously 
should produce additive effects in promoting axon regeneration. Consistent with this, deletion of both PTPσ 
and LAR enhanced adult neuronal axon growth on CSPGs in vitro to a greater degree than deletion of either 
receptor alone (Fig. 7a). Moreover, suppressing CSPG actions, when combined with other strategies that address 




CGNs N2A cells 
LAR-Transf
CGNs
ActivityPTPσ+/+ PTPσ−/− LAR+/+ LAR−/−
Active RhoA 1 ↑ p < 0.05 ↑ p < 0.05 ↔ p = 0.2664 ↑ p < 0.05 ↑ (Fisher et al.) ↔ (Fisher et al.) ↑ by both
p-Cofilin i 2 ↔ p = 0.234 ND ND ↑ p < 0.01 ↑ p < 0.05 ↔ p = 0.4838 ↓ by LAR
p-Akt 2 ↓ p < 0.01 ↓ p < 0.01 ↔ p = 0.879 ↓ p < 0.01 ↓ (Fisher et al.) ↔ (Fisher et al.) ↓ by both
p-S6 2 ↓ p < 0.01 ↓ p < 0.05 ↔ p = 0.8677 ↔ p = 0.147 ND ND ↓ by PTPσ 
p-4E-BP1 i 3 Trend ↓ P = 0.119 ND ND
Trend ↓ 
p = 0.154 ND ND
Trend ↑ by 
both
p-CRMP2 i 3 ↑ p < 0.01 ↑ p < 0.05 ↔ p = 0.9466 ↔ p = 0.163 ND ND ↓ by PTPσ 
p-APC 3 ↓ p < 0.01 ↓ p < 0.05 ↔ p = 0.9387 Trend ↓ P = 0.146 ND ND ↓ by PTPσ 
p-MAP1B 4 ↑ P < 0.01 ↑ p < 0.05 ↑ p < 0.05 ↑ p < 0.01 ↑ p < 0.05 ↔ p = 0.1922 ↑ by both
p-Erk 4 ↓ p < 0.01 ↓ p < 0.05 ↓ p < 0.05 ↓ p < 0.01 ↓ p < 0.05 ↓ p < 0.05 ↓ by both
p-p90RSK 5 ↔ p = 0.132 ND ND ↔ p = 0.232 ND ND ↔ by both
p-CREB 5 ↓ P < 0.05 ↓ p < 0.05 ↔ p = 0.9671 ↔ p = 0.193 ND ND ↓ by PTPσ 
p-LKB1 5 ↔ p = 0.302 ND ND ↓ p < 0.01 ↓ p < 0.05 ↔ p = 0.9189 ↓ by LAR
p-PKA 6 ↔ p = 0.923 ND ND ↔ p = 0.527 ND ND ↔ by both
p-PKCζ 6 ↔ p = 0.998 ND ND ↑ p < 0.01 ↓ p < 0.05 ↔ p = 0.3167 ↑ or ↓ by LAR
p-PKC(pan) 6 ↔ p = 0.563 ↔ p = 0.989 ↔ p = 0.6102 ↔ p = 0.358 ↔ p = 0.9205 ↔ p = 0.8006 ↔ by both
Table 1.  Comparison of signaling pathways downstream of PTPσ and LAR. Note: All phosphorylated 
proteins indicate their active form except for p-CRMP2, p-Cofilin, and p-4E-BP1, which are marked with i. ND: 
not determined.
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signaling pathways (e.g., PTEN, SOCS3, STAT3 and c-myc) or transcription factors (such as KLFs)38,98–100, may 
induce more robust axon regeneration than any single therapy alone. Combining axon regenerative strategies 
with task-specific rehabilitative training should further promote rewiring of appropriate neuronal circuits, rein-
forcing functionally meaningful synaptic reconnections and enhancing neuroplasticity after CNS injuries.
Materials and Methods
Ethical approval. All experimental protocols were approved by the Institutional Animal Care & Use Committee 
at Temple University and the methods were carried out in accordance with the relevant guidelines and regulations.
Sources of compounds. Antibodies against the following proteins were used: mouse mAb phospho-Akt 
(Ser473, 587F11), rabbit mAb phospho-S6 ribosomal protein (Ser235/236), rabbit mAb phospho-Erk1/2 
(p44/42), rabbit pAb phospho-CRMP2 (Thr514), rabbit pAb phospho-cofilin (Ser3), rabbit mAb phospho-4E- 
BP1 (eukaryotic initiation factor 4E-binding protein 1, Thr37/46, 236B4), rabbit mAb phospho-CREB (Ser133, 
87G3), rabbit mAb phospho-PKA C (Thr197, D45D3), rabbit pAb phospho-90 kDa ribosomal S6 kinase (p90RSK, 
Thr573), rabbit pAb phospho-PKCζ /λ (Thr410/403), rabbit mAb phospho-PKC (pan) (zeta Thr410, 190D10), 
rabbit mAb phospho-LKB1 (Ser428, C67A3) (all from Cell Signaling Technology), rabbit pAb phospho-MAP1B 
(Thr1265, Millipore), rabbit pAb phospho-APC (Ser2054, Abcam), mouse anti-actin clone C4 (MP Biomedicals) 
and mouse mAb against RhoA (sc-418; from Santa Cruz Biotechnology). The major proteins employed include 
rhotekin binding domain beads (binds active Rho protein, RT02-A, Cytoskeleton, Inc), a mixture of purified 
CSPGs (containing neurocan, versican phosphacan and aggrecan, Millipore), laminin (Sigma) and several pro-
tease inhibitors (see below, Sigma,). A plasmid with the human LAR sequence was provided by Dr. Morgan Sheng 
and amplified in our lab16,101. A plasmid with the human PTPσ sequence was generated and amplified in our lab.
N2A cell cultures and sample preparations. N2A, a mouse neural crest-derived cell line, pos-
sesses neuronal properties26 and is widely used to study neuronal differentiation, axonal growth and signaling 
pathways65–67,102,103. N2A cells were grown on poly-L-lysine-coated 35 mm dishes in Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 μ g/ml 
penicillin and 100 μ g/ml streptomycin. One day after growth, cells were transfected with control plasmid, WT 
LAR or PTPσ plasmid, using Xfect transfection reagents (Clontech Laboratories). Two days after transfection, 
cells were stimulated with vehicle or purified CSPGs (1.5 μ g/ml) for 5–120 minutes as indicated in Figs 1, 2, 3, 4, 
5 and 6. Following 3 washes with ice-cold PBS, cells were prepared in 300 μ l cold lysis buffer supplemented with 
protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 mM orthovanadate, 10 μ g/ml leupeptin and 10 μ g/ml 
aprotinin). Samples were clarified by centrifugation at 15,000 g for 10 min at 4 °C and total protein was deter-
mined with Bio-Rad DC protein assay reagents. Samples containing the same amount of total protein were then 
aliquoted into multiple tubes and stored at − 80 °C for biochemical assays.
PTPσ and LAR knockout mice and cerebellar granular neuron cultures. PTPσ and LAR knockout 
mice were provided by Drs. Michel Tremblay104 and Frank Longo105, respectively. PTPσ and LAR + /− littermate 
crosses were used to generate + /+ , + /− and − /− littermates. Genotyping was conducted by PCR (for PTPσ 
KO) or reverse transcription-PCR following the protocols from Dr. Longo’s Lab (for LAR KO)105. Homozygous 
and heterozygous PTPσ and LAR mutant mice are viable and grossly normal in appearance. Primary cerebellar 
granular neuron cultures were prepared from the cerebelli of postnatal 7–9 day mice derived from PTPσ + /+ , 
PTPσ − /− , LAR+ /+ or LAR− /− mice. After trypsin digestion, cells were dissociated and grown in culture 
medium (DMEM/F12 containing 10% fetal bovine serum, 2 mM glutamine, 100 μ g/ml penicillin and 100 μ g/ml 
streptomycin, 25 mM KCl and 25 mM glucose) for 24 hrs at 37 °C inside of 6-well plates. Before cell plating, the 
wells were prepared by coating with poly-L-lysine (100 μ g/ml) and incubating with 10 μ g/ml laminin for 2 hrs 
at 37 °C. NGF was not applied to neuronal cultures for neurite outgrowth assays. CGNs were then treated with 
purified CSPGs at indicated time points.
Active RhoA assay. Supernatant samples from N2A or CGN cultures (in 35 mm dishes) were prepared as 
above. After quantification of total proteins in lysates, using Bio-Rad DC protein assay reagents, a sample con-
taining the same amount of proteins from each dish was incubated with rhotekin binding domain coupled beads 
(45 μ g/sample) for 50 min at 4 °C. GTP-bound RhoA and total RhoA in cell lysates were detected by Western blot 
using a mouse monoclonal antibody against RhoA106. Proteins were transferred to nitrocellulose membranes and 
bands were visualized with enhanced chemiluminescence reagents as above. For blot densitometry, the images of 
active RhoA bands were captured with a Bio-Rad Gel Doc XR documentation system and the band density was 
determined using Quantity One software21. The intensity of an individual band was calculated by subtraction of 
the value of background in the same lane from which the band was measured, and then calibrated against the 
intensity of the total RhoA band.
Western blot assay. Expression changes of each studied signaling protein were determined with Western 
blots in N2A cells and CGNs after CSPG treatment. The supernatants of cell lysates containing the same amount 
of total proteins were loaded onto Tris-Glycine gels and transferred to nitrocellulose membranes. The membranes 
were blocked with 5% blotting grade milk (BIO-RAD), blotted with primary antibodies described above, and 
then incubated with appropriate secondary antibodies conjugated to IRDye 800CW (LI-COR) or IRDye 680RD 
(LI-COR). To determine the levels of loading control proteins, membranes were probed with anti-total signaling 
proteins and/or actin using separate membranes with the same amount of total loading proteins. Visualization 
and quantification were carried out with the LI-COR Odyssey® scanner and Odyssey® imaging software. For 
the Western blotting assays, at least three separate experiments were performed and the representative blots are 
shown in the figures.
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Dorsal root ganglion cultures and CSPG gradient assay for neurite outgrowth. DRGs were 
harvested from various genotypes of mice (6–7 weeks old, Fig. 7a) and incubated in collagenase (100 U/ml, 
Worthington Biochemical Corporation, Lakewood, NJ) and then with collagenase plus 0.25% trypsin/EDTA. 
After wash with culture medium, dissociated DRG neurons were plated onto plastic coverslips and grown in 
culture medium (DMEM/F12 mixture plus 10% fetal bovine serum, 2 mM glutamine, 100 μ g/ml penicillin and 
100 μ g/ml streptomycin) for 5 days at 37 °C21,35. Before cell plating, coverslips (15 mm) coated with poly-L-lysine 
were spotted with a 2-μ l solution of aggrecan (600 μ g/ml) and laminin (10 μ g/ml) in HBSS-CMF (2 spots/cov-
erslip). After complete dryness of the spots, coverslips were incubated with laminin (10 μ g/ml) in HBSS-CMF at 
37 °C for 2 hr. Five days after plating, DRG cultures were fixed in 4% paraformaldehyde in PBS for 30 min. After 
several rinses with PBS, coverslips were incubated in blocking solution (5% normal goat serum + 0.2% BSA in 
0.1% Triton X-100 PBS) for 1 hr at room temperature and then incubated with anti-β III-tubulin (1:400; Covance) 
overnight at 4 °C. After rinses several times with PBS, DRG cultures were incubated in appropriate secondary 
antibody (ThermoFisher Scientific) for 1 hr at RT. The number of β III-tubulin positive axons crossing spot rim 
(visualized by CS56 staining) were counted from each spot. Multiple coverslips were employed for each group of 
individual experiments.
Statistical analysis. SigmaPlot software was used for statistical analysis. Data in graphs are shown as 
means ± SEM. The comparisons between multiple groups were analyzed with a repeated measures ANOVA. The 
experiments comparing a single determination of means between two independent groups, including the active 
RhoA and neurite growth assay, were analyzed with Student’s t-test. Differences between groups with p < 0.05 
were considered significant (*p < 0.05, **p < 0.01). Quantification data for each signaling protein were collected 
from 3–5 separate experiments.
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